Disease, Development, and Population Change

Throughout the twentieth century, diseases and scientific advancements significantly influenced global populations, shaping health outcomes across a world that grew from 1.6 billion in 1900 to 6 billion by 2000. Diseases—defined as illnesses that impact human health and survival—persisted or emerged as epidemics, while others became more common as people lived longer. At the same time, medical innovations transformed the ability of societies to respond to these challenges.

Poverty played a major role in the spread of disease after 1900, particularly in regions with limited access to sanitation, healthcare, and resources. By 1950, approximately 50 percent of the global south was affected by diseases linked to poverty. In contrast, more developed regions with stronger healthcare systems experienced lower mortality rates and faster access to medical innovations. At the same time, new epidemics disrupted societies worldwide, claiming millions of lives, while longer lifespans introduced new health challenges. These combined pressures drove scientific and medical advancements that reached approximately 80 percent of humanity by the end of the century.

The interaction between disease and development transformed global demographics and economies. Persistent illnesses tied to poverty killed approximately 20 million people annually by 1950, while epidemics such as the 1918 influenza pandemic affected 500 million people worldwide. Medical developments—including new treatments and technologies—helped counter these threats by reducing mortality. As a result, life expectancy increased from 31 years in 1900 to 66 years by 2000. These advances supported approximately 70 percent of global population growth, as innovations reduced mortality for billions by the late twentieth century. This demonstrates how medical advancements were a key driver of population growth and demographic change in the modern era.

The development of the polio vaccine in 1955 by Jonas Salk illustrates this transformation. Introduced on April 12, the vaccine targeted a disease that affected 500,000 people annually, with 20 percent of cases resulting in paralysis. Within a decade, 100 million people had been vaccinated globally, reducing cases in the United States by 90 percent by 1965. This breakthrough improved child survival rates, contributing to a 30 percent decline in infant mortality in developed nations by 1970 and reaching 50 percent of the world’s children by 1980. This example demonstrates how medical innovation directly improved health outcomes and contributed to long-term population growth, especially in regions with access to healthcare infrastructure.

Persistent Diseases of Poverty: Malaria

Malaria remained one of the most persistent global health threats throughout the twentieth century, closely linked to poverty and environmental conditions. Malaria is a mosquito-borne disease that causes fever and organ damage, infecting approximately 200 million people annually by 1950 across a global population of 2.5 billion. It thrived in tropical regions with limited sanitation, particularly in Africa and Asia, where 90 percent of cases occurred by 1970. In contrast, wealthier regions with stronger public health systems largely eliminated malaria, demonstrating the role of economic development in disease control. Millions died each year—approximately 5 million in 1950—disproportionately affecting populations in sub-Saharan Africa and South Asia.

Efforts to combat malaria highlight both the potential and limitations of medical intervention. The introduction of DDT insecticide in the 1940s reduced infections significantly, cutting global cases by 50 percent by 1960. By 1955, DDT had been applied across 1 billion hectares, saving approximately 10 million lives annually. However, these gains were not permanent. By 1970, mosquito resistance to DDT emerged, and cases increased by 20 percent by 1980. This shows that technological solutions alone were not always sufficient to eliminate disease.

Poverty remained a major barrier to eradication. Approximately 60 percent of affected regions lacked the financial resources—estimated at $1 billion annually—needed to sustain prevention efforts such as mosquito nets and medical treatments. As a result, 2 billion people remained at risk, and malaria continued to kill approximately 1 million people annually by 2000. This demonstrates how economic inequality limited the effectiveness of medical solutions, showing that disease persistence was closely tied to broader patterns of global inequality.

The World Health Organization’s Malaria Eradication Campaign of the 1950s and 1960s illustrates these challenges. Launched in 1955, the campaign reduced cases in India from 75 million annually to 100,000 by 1969 across a population of 550 million. Despite saving approximately 2 million lives annually, poverty limited long-term success, and cases rebounded to 6 million by 1976. This example demonstrates that while international organizations like the World Health Organization could coordinate large-scale responses, long-term success depended on sustained economic development and global cooperation.

Tuberculosis and Cholera: Disease and Inequality

Tuberculosis (TB) and cholera, both closely associated with poverty, continued to affect populations throughout the twentieth century, highlighting the relationship between disease and socioeconomic conditions. Tuberculosis is a bacterial lung infection that spreads in crowded, impoverished environments, infecting approximately 10 million people annually by 1950. Cholera, a waterborne disease caused by contaminated water, remained prevalent in areas lacking sanitation, killing approximately 100,000 people annually by 1900.

These diseases had significant social and economic effects. Tuberculosis caused approximately 3 million deaths annually by 1950, while cholera outbreaks disrupted urban life and trade, affecting 50 million people in cities by 1970. In developed regions, improved sanitation systems and access to antibiotics significantly reduced these diseases. In contrast, developing regions continued to struggle due to limited infrastructure and resources. Antibiotics introduced in the 1940s, such as streptomycin, reduced TB deaths by 50 percent by 1970, while improved sanitation systems reduced cholera cases by 70 percent in Europe by 1950. This demonstrates how scientific and infrastructural developments could significantly reduce disease impact, but uneven access created global disparities.

Despite these advances, poverty continued to drive disease persistence. By 1960, India experienced approximately 2 million TB cases annually, and by 1990, 20 percent of the urban poor lacked access to clean water, increasing vulnerability to cholera. Although public health improvements reached 80 percent of nations by 1990, approximately 2 billion people remained at risk due to ongoing economic inequality. This shows that medical progress alone was insufficient without addressing underlying social and economic conditions.

The 1991 cholera epidemic in Peru illustrates this relationship. The outbreak infected 300,000 people and killed 3,000 within a year, largely due to poor water systems. It disrupted trade, reducing fish exports by $500 million, and led to sanitation reforms that reached 50 million people by 1995. Cases declined by 90 percent by 1996, saving 100,000 lives annually. This example demonstrates how public health responses can reduce disease while also highlighting the ongoing role of poverty in shaping health outcomes.

The 1918 Influenza Pandemic: A Global Crisis

The 1918 influenza pandemic was one of the most devastating epidemics in modern history, reshaping societies and influencing future medical research. Epidemics—defined as sudden and widespread disease outbreaks—can have profound social and economic consequences. The 1918 flu killed approximately 50 million people worldwide, or about 3 percent of the global population of 1.8 billion, and infected 500 million people across five continents.

The rapid spread of the disease exposed global vulnerabilities, particularly in the aftermath of World War I. The pandemic overwhelmed healthcare systems, with hospitals unable to handle the surge of patients. Approximately 20 percent of cases were severe, and quarantine measures affected 100 million people. Economic disruption was widespread, with trade halted for approximately 500 million people and global losses estimated at $200 billion. This shows how epidemics could cause both immediate human loss and large-scale economic disruption.

The scale of the crisis accelerated medical research and public health efforts. By 1930, approximately 70 percent of nations had adopted influenza research programs, and by 1970, vaccination efforts reached 100 million people annually. This demonstrates how major epidemics not only caused immediate devastation but also accelerated long-term scientific innovation and government involvement in public health. In response, governments and international organizations increasingly collaborated to monitor and prevent future outbreaks, reflecting growing global cooperation.

India provides a powerful example of the pandemic’s impact. Approximately 17 million people—5 percent of the population—died, with the rural poor disproportionately affected. The crisis disrupted trade and prompted public health reforms, such as the 1920 Public Health Act. Although progress was limited by economic constraints, the pandemic ultimately contributed to long-term improvements in global health systems.

New Epidemics: Ebola and HIV/AIDS

New diseases such as HIV/AIDS and Ebola emerged in the late twentieth century, presenting significant global challenges. HIV/AIDS, first recognized in 1981, spread globally through blood and sexual contact, infecting millions. By 2010, HIV/AIDS had infected approximately 36 million people worldwide. The disease had a particularly severe impact on sub-Saharan Africa, where infection rates were highest and healthcare systems were often under-resourced. In some regions, HIV/AIDS reduced life expectancy by up to 10 years, affecting tens of millions of people and placing major strain on families, labor systems, and national economies.

HIV/AIDS also had a disproportionate impact on LGBTQ populations, particularly gay men in the United States and Western Europe during the early years of the epidemic in the 1980s. Due to limited medical knowledge, social stigma, and discrimination, these communities often faced delayed government response and inadequate access to healthcare. Activist groups such as ACT UP (AIDS Coalition to Unleash Power) organized protests to demand increased research funding, faster drug approval, and public awareness. These efforts led to greater investment in treatment and contributed to the development of antiretroviral therapies in the 1990s. This demonstrates how social inequality and discrimination shaped the impact of disease, while also showing how grassroots activism influenced medical and political responses.

Governments and international organizations responded to the HIV/AIDS crisis with education campaigns that reached approximately 1 billion people and major financial investments totaling about $10 billion annually by 2010. Scientific advancements played a critical role in reducing the impact of the disease. Antiretroviral drugs, developed in the 1990s, reduced HIV-related deaths by 50 percent, saving approximately 1 million lives annually by 2015. These efforts demonstrate how global cooperation and medical innovation helped reduce the impact of a rapidly spreading disease, even as inequality continued to shape outcomes across different regions.

Ebola, first identified in 1976, caused deadly outbreaks primarily in Central and West Africa. Unlike HIV/AIDS, Ebola spread through direct contact with infected bodily fluids and had extremely high mortality rates, reaching as high as 50 percent in some outbreaks. By 2010, Ebola had affected populations across regions totaling 50 million people, with the most severe impacts concentrated in West African nations with limited healthcare infrastructure. Outbreaks devastated local communities, overwhelming hospitals and disrupting economic activity, trade, and daily life.

Quarantine and containment strategies were essential in limiting the spread of Ebola, protecting millions of people from infection. The 2014 Ebola outbreak in Sierra Leone highlights these developments. The outbreak killed 4,000 people and overwhelmed healthcare systems, but global research efforts and international aid helped contain the spread of the disease. By 2019, scientists developed an effective vaccine, saving thousands of lives annually and improving response efforts for future outbreaks. This demonstrates how globalization contributed to the rapid spread of disease but also enabled faster global responses through international cooperation and scientific innovation, particularly in regions most affected by limited healthcare resources.

Diseases of Longevity: Heart Disease and Alzheimer’s

As life expectancy increased, new health challenges emerged, particularly diseases associated with aging. Longevity—defined as extended life expectancy—rose significantly after 1945, with global averages increasing from 48 to 66 years by 2000. As a result, diseases such as heart disease became leading causes of death in developed nations.

Heart disease, often linked to diet, lifestyle, and aging, caused approximately 7 million deaths annually by 1990. In developed countries, where more people lived beyond age 65, it accounted for up to 30 percent of deaths by 2000. In contrast, developing regions continued to face higher mortality from infectious diseases, demonstrating differing health challenges based on level of development. Medical advancements such as bypass surgery and stents improved survival rates, demonstrating how healthcare systems adapted to new challenges created by longer lifespans. This illustrates how medical advancements created new challenges, as longer life expectancy led to an increase in chronic diseases.

Alzheimer’s disease represents another major challenge associated with longevity. This neurological disorder affects memory and cognitive function, primarily in elderly populations. By 1990, approximately 5 million people worldwide were affected, and cases increased significantly in aging societies such as Japan. By 2020, approximately 50 million people globally had Alzheimer’s, highlighting the growing burden of age-related diseases.

The rise of these diseases demonstrates a key historical pattern: medical advancements that extend life can also create new health challenges. Governments and healthcare systems responded with increased research, spending billions annually, and developing new treatments and care systems. These changes affected hundreds of millions of people and illustrate the complex relationship between technological progress and human health.

Connecting the Patterns

Across the twentieth century, disease and medical innovation were closely linked to broader patterns of global development. Diseases of poverty continued to affect less developed regions, demonstrating how inequality limited access to healthcare and sanitation, while more developed regions experienced lower mortality rates due to stronger infrastructure. At the same time, major epidemics such as the 1918 influenza pandemic, HIV/AIDS, and Ebola revealed the increasing interconnectedness of the world, as diseases spread rapidly across regions.

Medical advancements, including vaccines and antibiotics, reduced mortality and increased life expectancy, contributing to rapid population growth. However, these successes also created new challenges, as longer lifespans led to the rise of chronic diseases such as heart disease and Alzheimer’s. Together, these patterns show that while scientific progress improved human survival, it also introduced new health challenges and highlighted ongoing global inequalities.